Valuation: Precipio Inc

Market Cap 38.7M 33.64M 31.31M 28.75M 54.29M 3.69B 55.13M 369M 145M 1.84B 145M 142M 6.17B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 39.7M 34.51M 32.12M 29.49M 55.69M 3.79B 56.55M 379M 149M 1.89B 149M 146M 6.33B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.35%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 31/05/2017
Chief Executive Officer 54 27/06/2017
Director TitleAgeSince
Director/Board Member 54 27/06/2017
Director/Board Member 78 25/09/2017
Director/Board Member 67 07/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
+20.04%-15.97% - - 38.7M
-1.89%-1.36%+19.78%-40.36% 15.7B
+4.47%+7.46%+3.82%+107.97% 1.77B
+1.21%+4.49%-26.48%-80.29% 1.14B
-1.73%+2.33%-33.93%+16.19% 980M
+1.29%+7.31%-44.39%-52.50% 655M
+0.93%+7.41%-45.64%-53.16% 543M
+1.08%+2.47%+55.85%-51.37% 472M
-0.81%+1.33%-52.64%-61.03% 374M
-0.81%+5.14%-13.72%-32.63% 368M
Average +2.38%+2.54%-15.26%-27.46% 2.45B
Weighted average by Cap. -0.91%-0.19%+9.16%-29.10%

Financials

2024 2025
Net sales 18.53M 16.11M 14.99M 13.77M 26M 1.77B 26.4M 177M 69.37M 881M 69.6M 68.07M 2.95B 24.05M 20.91M 19.46M 17.87M 33.74M 2.3B 34.26M 229M 90.02M 1.14B 90.32M 88.33M 3.83B
Net income -4.29M -3.73M -3.47M -3.19M -6.02M -410M -6.11M -40.92M -16.06M -204M -16.11M -15.76M -684M -363K -316K -294K -270K -509K -34.65M -517K -3.46M -1.36M -17.25M -1.36M -1.33M -57.85M
Net Debt -136K -118K -110K -101K -191K -12.98M -194K -1.3M -509K -6.46M -511K -500K -21.67M 1M 871K 811K 744K 1.41M 95.65M 1.43M 9.56M 3.75M 47.62M 3.76M 3.68M 160M
Logo Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-